54 results about "Peg interferon" patented technology

The present invention belongs to the field of pharmaceutical technology and clinical pharmacy, relates to a cyclopeptide containing arginine-glycine-aspartic acid (RGD) sequence and its active liposome targeting, its preparation and application. The described cyclopeptide structure meets the requirements as ligand, and is cyclized by amido bond, its spatial conformation is stable, and is not easily degraded, its one end contains active sulphydryl group, and is convenient for modifying artificially-synthetic function peptide, its molecular weight is small, so that it is not easy to result in immune reaction, and can be used as ligand, and can be combined with hepatic stellate cell (HSC) surface integrator acceptor to construct active liposome targeting and implement target therapy for experimental hepatic fibroid cell. Said invention can obtain good therapeutic effect for curing hepatitis fibrosis.

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

The present invention relates to the stable pharmaceutical compositions comprising PEG- interferon alpha-2b. More particularly, it relates to the stable pharmaceutical compositions comprising PEG-interferon alpha-2b and cryoprotectant selected from the group consisting of 2-Hydroxy propyl beta-cyclodextrin, sucralose, or polyvinylpyrrolidone 4000. It also relates to the methods of manufacturing the composition, method of administration and kits containing the same.

The present invention provides methods of decreasing the frequency of emergence, decreasing the level of resistance, and delaying the emergence of a treatment-resistant Hepatitis C viral infection, by administering to a subject, either in combination or in series, an inhibitor of the Hepatitis C RNA-dependent RNA polymerase NS5B, e.g., a benzofuran, such as 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide (HCV-796), and at least one additional anti-Hepatitis C agent, e.g., a ribavirin product or an immunomodulator, such as an interferon product. Additionally, the invention relates to methods of monitoring the course of treatment of a Hepatitis C viral infection, methods of monitoring and prognosing a Hepatitis C viral infection, and methods of identifying an individual with a decreased likelihood of responding to an anti-Hepatitis C viral therapy. These methods use the sequence and / or structure of the Hepatitis C RNA-dependent RNA polymerase NS5B to identify the emergence of a treatment-resistant Hepatitis C viral infection, particularly a benzofuran (e.g., HCV-796) treatment-resistant Hepatitis C viral infection.

The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms.

The present invention relates to the field of ribavirin anti-derivative viruses, and discloses a ribavirin derivative (as shown in formula (I)) combined with α-interferon in the manufacture of treatment and / or prevention of viral infection and Use in medicine for related diseases caused by viral infection, pharmaceutical composition containing ribavirin derivatives and α-interferon and use of the pharmaceutical composition for preventing viral infection and related diseases caused by viral infection. The combined use of the ribavirin derivative represented by the general formula (I) of the present invention and α-interferon has a significantly better virus-inhibiting effect, and has no side effects.